Mammotome, a globally recognized leader in breast care, and Sirius Medical, the innovator of Surgical Marker Navigation, are proud to announce an exclusive distribution agreement for the United States and Germany. This collaboration combines the extensive breast care knowledge and commercial capabilities of Mammotome with Sirius Medical’s technology and innovation.
Breast cancer remains a significant health challenge globally, highlighting the urgent need for advanced technologies to improve patient outcomes and streamline surgical procedures. The Sirius Pintuition System represents a major advancement in this field, offering surgeons enhanced accuracy and efficiency by replacing traditional localization methods with Surgical Marker Navigation for precise tumor excision.
“We are thrilled to partner with Mammotome in our mission to advance breast cancer care,” said Bram Schermers, Chief Executive Officer of Sirius Medical. “This collaboration will allow us to expand our footprint in critical markets and empower more surgeons with precise, efficient tools that transform patient outcomes.”
As a leading provider of innovative breast cancer diagnostic and surgical solutions, Mammotome is uniquely positioned to bring the Pintuition System to market, supported by a deep understanding of the needs of breast care professionals and their patients. Through this collaboration, Mammotome will leverage its extensive sales network across the United States and Germany, ensuring that healthcare facilities and surgeons have seamless access to Sirius Medical’s latest technology, along with Mammotome’s full portfolio of premium breast care products.
“The Pintuition System aligns with Mammotome’s commitment to bring innovative, high-quality solutions to healthcare providers and their patients,” said Mammotome Senior Vice President and Chief Commercial Officer Sarah Moore. “We’re excited to introduce this advanced technology to healthcare facilities and help enhance the quality of care for breast cancer patients.”
This partnership reinforces both companies’ dedication to driving progress in breast cancer treatment by providing state-of-the-art tools that facilitate optimal care. The Pintuition System will soon be available to an even broader network of surgical facilities, expanding access to advanced breast care technology. Further, this product will complement the Neoprobe Gamma Detection System and the HydroMARK Plus Breast Biopsy Site Marker, affording clinicians a suite of premium technologies for all their breast surgical needs.
